DUAL-TARGET FUSION PROTEINS COMPRISING FGF21 AND GLP-1, CONNECTED THROUGH A FC PORTION OF AN IMMUNOGLOBULIN
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 13, 2025
app pub date -
Aug 15, 2024
filing date -
Aug 15, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully